Last reviewed · How we verify
Combination Agent 1 (combination-agent-1)
At a glance
| Generic name | combination-agent-1 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Arthralgia
- Pain In Extremity
- Myalgia
- Dizziness
- Back Pain
- Dyspnoea
- Fatigue
- Cough
- Chest Pain
- Nasopharyngitis
- Muscle Spasms
- Musculoskeletal Pain
Key clinical trials
- A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers (PHASE1, PHASE2)
- AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) (PHASE1, PHASE2)
- Optimisation Strategy for Emergency Tracheal Intubation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination Agent 1 CI brief — competitive landscape report
- Combination Agent 1 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI